Stay updated with breaking news from Dose Optimization Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual
- Plenary Scientific Session to highlight Incyte-discovered novel anti-mutant CALR-targeted monoclonal antibody INCA033989 - Data from three of the Company's LIMBER studies evaluating ruxolitinib
Influenza vaccine candidate OVX836 safety profile and efficacy signals from Phase 2a dose-optimization study to be presented at UIV 2022 Preclinical proof of cross-protection against SARS-COV-2
Excellent safety continues to be observed in ongoing Phase 2a dose optimization study (OVX836-003) Phase 2a dose optimization study extended to elderly population cohort (OVX836-003)